Browse All

Current Filters

CLEAR FILTER x

TITLE

Title
    Author Last Name
      Session Name
        Topic
          Program Number
            Author Institution

              Results from a 36-Week Open-Label Study of Recombinant Human Growth Hormone and Testosterone in Facioscapulohumeral Muscular Dystrophy (FSHD)

              Author:Heatwole, Chad   Luebbe, Elizabeth   Hamel, Johanna   Mongiovi, Philip   Ciafaloni, Emma   Dilek, Nuran   Martens, William   Weber, David   Hani, Rashid   Allen, Jamie   Smith, Claire   Howell, Samantha   Rosero, Spencer   Eichinger, Katy   Baker, Linday   Dekdebrun, Jeanne   Hilbert, Jim   Varma, Anika   McDermott, Michael   Thornton, Charles   Moxley, Richard   

              Session Name:S48: Therapeutics for Muscle Disease  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S48.009  

              Author Institution:University of Rochester Medical Center, Rochester, NY  Children's Hospital of Philadelphia, Philadelphia, PA  University of Rochester Medical Center, Baltimore, MD  

              Annualized Rates of Change from A Phase 2, Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of Losmapimod in Subjects with FSHD: ReDUX4

              Author:Tawil, Alrabi   

              Session Name:S48: Therapeutics for Muscle Disease  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:S48.010  

              Author Institution:University of Rochester Medical Center, Rochester, NY  

              Valbenazine Decreases Disease Burden in Patients with Chorea Associated with Huntington Disease: Patient-Reported Huntington Disease Health Index (HD-HI) Results From the KINECT-HD Trial

              Author:Heatwole, Chad   Furr Stimming, Erin   Claassen, Daniel   Kayson, Elise   Goldstein, Jody   Klepitskaya, Olga   Liang, Grace   Haubenberger, Dietrich   

              Session Name:P2: Movement Disorders: Huntington's Disease and Chorea 2  

              Topic:Movement Disorders  

              Program Number:P2.012  

              Author Institution:University of Rochester Medical Center, Rochester, NY  The University of Texas Health Science Center at Houston, McGovern Medical School, Houston, TX  Vanderbilt University Medical Center, Nashville, TN  Huntington Study Group, Rochester, NY  Neurocrine Biosciences, Inc, San Diego, CA  Neurocrine Biosciences, Inc., San Diego, CA  Neurocrine Biosciences, San Diego, CA  

              Treatment Recommendations and Estimation of Toxicity in Older Patients with Glioblastoma

              Author:Hemminger, Lauryn   Whitt, Wade   Cawley, Sarah   Behr, Jacqueline   Serventi, Jennifer   Wasilewski, Andrea   Mohile, Nimish   Hardy, Sara   

              Session Name:P3: Neuro-oncology: Advancing Care for Patients with Brain Tumors  

              Topic:Neuro-oncology  

              Program Number:P3.001  

              Author Institution:University of Rochester Medical Center, Rochester, NY  Givens Brain Tumor Center, Minneapolis, MN  

              Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of AOC 1020 Administered Intravenously to Adult Patients with Facioscapulohumeral Muscular Dystrophy (FORTITUDE) Trial Design

              Author:Halseth, Amy   Ackermann, Elizabeth   Brandt, Teresa   Chen, Chao-Yin   Stahl, Mark   Ditrapani, Kelly   Hughes, Steve   Tawil, Alrabi   Statland, Jeffrey   

              Session Name:P3: Neuromuscular Disease: Inherited Muscle Disorders 1  

              Topic:Neuromuscular and Clinical Neurophysiology (EMG)  

              Program Number:P3.007  

              Author Institution:Avidity Biosciences, San Diego, CA  Avidity Biosciences, La Jolla, CA  Avidity Biosciences, HALF MOON BAY, CA  University of Rochester Medical Center, Rochester, NY  University of Kansas Medical Center, Kansas City, KS